Research Library › Research Desk
A headline that says a peptide “was shown to” do something can rest on anything from a single cell-culture experiment to a large randomized trial. Ask six questions before trusting a peptide study: what was studied, in what, who funded it, was it controlled, has it been replicated, and has it been corrected or retracted. This guide explains each one.
1. What kind of study is it?
Evidence comes in layers. In vitro studies use cells or isolated proteins in a dish. Animal studies use rodents or other species. Human studies range from small case reports through observational studies to controlled clinical trials. Results often fail to carry from one layer to the next. A finding in cultured cells tells you about cells under those conditions, not about a living body. Every compound page in our library states which layers of evidence exist.
2. What phase was the trial?
Clinical trials are grouped into phases [2]. Phase 1 studies are small and focus on safety and how a compound is handled by the body. Phase 2 studies are larger and explore the design for later trials. Phase 3 trials are large, often multinational, and are usually what regulators review for approval. A Phase 1 result is not evidence that something works.
3. Was there a control group, and was it randomized?
Without a comparison group, it is hard to separate an effect from chance, from the natural course of a condition, or from expectation. Randomization, assigning participants to groups by chance, and blinding, hiding who received what, are the main protections against bias [1].
4. Was it registered in advance?
Trials registered on ClinicalTrials.gov or a similar registry before they start declare their main outcome up front [1]. Comparing the registered outcome with the published one shows whether the goalposts moved. Many compounds discussed online have no registered human trial at all, and our pages say so when that is the case.
5. Who did the work, and has anyone else repeated it?
Check the authors’ affiliations and funding statements. A literature that comes almost entirely from one laboratory, or from the compound’s developer, is weaker than one with independent replication. That does not make it wrong, but it should be read with that in mind.
6. Has the paper been corrected or retracted?
Journals issue corrections, expressions of concern and retractions when problems come to light [3]. PubMed marks retracted papers. Before relying on a paper, check its PubMed record and the journal page for notices. Our dihexa page is an example where these notices matter.
A note on purity and identity
Studies of research peptides only mean something if the material tested was what the label said. Look for methods that report identity (mass spectrometry) and purity (HPLC). Our guide How to read a peptide Certificate of Analysis explains these tests.
Sources
- U.S. National Library of Medicine. ClinicalTrials.gov: glossary of common site terms (phases, randomization, registration). Link
- U.S. FDA. Step 3: Clinical research (Phase 1–3 and Phase 4 definitions). Link
- Committee on Publication Ethics (COPE). Retraction guidelines. Link
The Kalibra Research Desk reports on published research and regulatory actions. It does not give medical, dosing or usage advice, and nothing here describes use in people or animals. Kalibra Labs products are for laboratory research use only.
